Creative Planning
JNCE

Creative Planning’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Creative Planning’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-59,789
Closed -$371K – 2150
2019
Q1 		$371K Sell
59,789
-601
-1% -$2.9K ﹤0.01% 1210
2018
Q4 		$204K Buy
60,390
+38,399
+175% +$179K ﹤0.01% 1479
2018
Q3 		$143K Buy
+21,991
New +$164K ﹤0.01% 1734

Other funds holding JNCE

TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Creative Planning's JNCE Position: Q2 2019 in Review

Creative Planning sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2019, closing a stake of 59,789 shares — an estimated $371K sold.

Creative Planning first reported a position in JNCE in Q3 2018 and held it in 3 quarters. The position peaked at $371K in Q1 2019. 80 funds tracked by Wall St. Rank hold JNCE as of Q2 2019.

  • Creative Planning reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • Creative Planning sold 59,789 Jounce Therapeutics, Inc. Common Stock shares in Q2 2019, an estimated $371K.
  • Creative Planning first reported a position in Jounce Therapeutics, Inc. Common Stock in Q3 2018 and held it in 3 quarters.
  • Creative Planning's Jounce Therapeutics, Inc. Common Stock position peaked at $371K in Q1 2019.
  • 80 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2019.

Based on Creative Planning's 13F filing for Q2 2019, filed 26 Jul 2019.